XUAB 2023-IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated with NeoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT Study

Grant

Total Award Amount

  • 216315.00
  • Direct Costs

  • 166396.00
  • Sponsor Award Id

  • Contributor

  • Ahmed Elkhanany   Principal Investigator  
  • Erica Stringer-Reasor M.D.   Investigator